Once-weekly basal insulin performs as well as once-daily glargine in trial

In the phase 3a ONWARDS 4 trial involving 582 adults with long-standing type 2 diabetes on a basal-bolus regimen, once-weekly icodec led to similar improvements in glycemic control at 26 weeks, with fewer basal insulin injections, lower bolus insulin dose, and no increase in hypoglycemic events compared with once-daily glargine U100.